Curated News
By: NewsRamp Editorial Staff
April 17, 2025
Calidi Biotherapeutics Receives FDA Clearance for Innovative Cancer Therapy
TLDR
- Calidi Biotherapeutics gains FDA clearance for innovative virotherapy CLD-201, targeting hard-to-treat cancers.
- CLD-201 combines adipose-derived stem cells with oncolytic vaccinia virus, showcasing immune system evasion and tumor-killing ability.
- CLD-201's clearance offers hope for patients with breast cancer, head and neck cancer, and soft tissue sarcoma, advancing cancer treatment.
- Calidi Biotherapeutics introduces novel stem cell-based virotherapy CLD-201, revolutionizing immunotherapeutic approaches for solid tumors.
Impact - Why it Matters
This news matters as it highlights a breakthrough in cancer treatment with the FDA clearance of a novel stem cell-based virotherapy. The therapy's immune system empowerment and tumor-killing ability offer hope for patients with hard-to-treat cancers. InvestorWire's role in communication showcases the importance of disseminating such groundbreaking advancements to the investment community.
Summary
Calidi Biotherapeutics (NYSE American: CLDI) receives FDA clearance for its Investigational New Drug application for CLD-201, a stem cell-based virotherapy targeting solid tumors. The therapy combines adipose-derived stem cells with oncolytic vaccinia virus to treat hard-to-treat cancers.
Calidi Biotherapeutics specializes in technology empowering the immune system to combat cancer. Their platforms utilize allogeneic stem cells carrying oncolytic viruses for multiple oncology indications. InvestorWire is a communications platform providing press release syndication for companies and the investment community.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Calidi Biotherapeutics Receives FDA Clearance for Innovative Cancer Therapy
